GlassScriptPhysician profile
April Roemer
NPI 1487312393
$5,019.92
in general payments reported to CMS, 2019-2025
53 companies · $4,068 in 2025
The $4,068 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.63 · 2023: $141 · 2024: $740 · 2025: $4,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355 · Education: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.11 |
| Education | $594.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $373.42 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals LP | $294.49 | 2024-2025 | Enhertu, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $279.68 | 2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $241.71 | 2023-2025 | |
| Genzyme Corporation | $225.18 | 2023-2025 | |
| Genentech USA, INC. | $204.38 | 2024-2025 | Tecentriq, Polivy, Lunsumio |
| Exelixis INC. | $201.13 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $188.29 | 2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $159.37 | 2024-2025 | |
| Celgene Corporation | $157.17 | 2024-2025 | Reblozyl, Pomalyst, Opdualag |
| Novocure INC. | $152.00 | 2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $143.80 | 2023-2025 | |
| Daiichi Sankyo INC. | $135.13 | 2025 | Enhertu |
| Beone Medicines USA, INC. | $128.73 | 2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $128.64 | 2025 | Onivyde |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $124.83 | 2024-2025 | Ultomiris |
| Kite Pharma, INC. | $124.46 | 2024 | Yescarta |
| Eisai INC. | $122.85 | 2024-2025 | |
| Amgen INC. | $120.80 | 2025 | Imdelltra (Amg757) |
| Sobi, INC | $108.05 | 2023-2025 | |
| Puma Biotechnology, INC. | $102.76 | 2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Astellas Pharma US INC | $92.37 | 2025 | Vyloy, Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.66 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $73.77 | 2025 | Libtayo, Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $64.77 | 2025 | Ninlaro, Alunbrig, Vpriv |
| Array Biopharma INC | $63.03 | 2025 | Braftovi, Tukysa, Mektovi |
| Jazz Pharmaceuticals INC. | $56.75 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $55.13 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Emd Serono, INC. | $45.31 | 2024-2025 | |
| Beigene USA, INC. | $44.89 | 2025 | Tevimbra, Brukinsa |
| Incyte Corporation | $41.99 | 2025 | Monjuvi, Zynyz, Jakafi |
| Dendreon Pharmaceuticals LLC | $39.48 | 2025 | Provenge |
| Csl Behring | $38.22 | 2022-2023 | Idelvion |
| Tersera Therapeutics LLC | $33.66 | 2025 | Zoladex |
| Glaxosmithkline, LLC. | $33.53 | 2025 | Jemperli, Zejula, Ojjaara |
| Iovance Biotherapeutics, INC. | $31.40 | 2025 | Amtagvi |
| Novo Nordisk INC | $30.98 | 2022-2024 | Rebinyn, Novoseven, Novoeight |
| Karyopharm Therapeutics INC. | $27.65 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $26.66 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.83 | 2025 | Opdivo |
| Servier Pharmaceuticals LLC | $24.75 | 2025 | |
| Duchesnay USA Incorporated | $23.66 | 2023 | Siklos |
| Legend Biotech USA INC. | $22.68 | 2025 | Carvykti |
| Medunik USA INC. | $21.89 | 2024 | Siklos |
| Geron Corporation | $21.28 | 2025 | Rytelo |
| Abbvie INC. | $19.18 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $18.77 | 2025 | Sancuso |
| Taiho Oncology, INC. | $18.45 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.91 | 2025 | Givlaari |
| Fennec Pharmaceuticals, INC. | $14.23 | 2025 | Fyarro |
| Pharmaand Gmbh | $8.18 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Roemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.